Dancing with Cancer Cells
Spotting the Baubles amongst the Glitter
Readers in the UK who follow the BBC show ‘Strictly Come Dancing’ will know this Saturday night the show returns to the iconic Tower Ballroom in Blackpool. All the contestants wanted to make it to this stage of the competition.
To put this analogy in context, an oncology equivalent might be the prestige of giving an oral presentation at a major medical meeting, it’s something you definitely remember and want to do!
There are many metaphors related to dancing that can apply to cancer research e.g. we’ve heard one leading researcher describe how immune cells and cancer cells ‘dance’ together. As they say, it takes two to tango…
How new products ’embrace’ and interact with cancer cells, their receptors and binding sites can be key to therapeutic success. There are a variety of ways to do this, one of which can lead to cancer cell death via synthetic lethality, a concept we’ve covered extensively over many years going back to the emergence of PARP inhibitors in 2006.
In this post, we’re taking a closer look at an emerging biotech company, their drug discovery pipeline, and some innovative targets that may enable their new drugs to better ‘dance’ with cancer cells in a way that interrupts their routine, and ultimately, leads to their death.
Keep on dancing!
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
